JP2019535651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535651A5 JP2019535651A5 JP2019517873A JP2019517873A JP2019535651A5 JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5 JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019517873 A JP2019517873 A JP 2019517873A JP 2019535651 A5 JP2019535651 A5 JP 2019535651A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- seq
- patient
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403786P | 2016-10-04 | 2016-10-04 | |
| US62/403,786 | 2016-10-04 | ||
| PCT/US2017/055055 WO2018067646A1 (en) | 2016-10-04 | 2017-10-04 | Compounds and methods for activating tie2 signaling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535651A JP2019535651A (ja) | 2019-12-12 |
| JP2019535651A5 true JP2019535651A5 (enExample) | 2020-11-19 |
Family
ID=61832135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517873A Pending JP2019535651A (ja) | 2016-10-04 | 2017-10-04 | Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190225670A1 (enExample) |
| EP (1) | EP3522906B1 (enExample) |
| JP (1) | JP2019535651A (enExample) |
| KR (1) | KR20190066040A (enExample) |
| CN (1) | CN110177563A (enExample) |
| AU (1) | AU2017339970A1 (enExample) |
| BR (1) | BR112019006735A2 (enExample) |
| CA (1) | CA3038809A1 (enExample) |
| EA (1) | EA201990868A1 (enExample) |
| IL (1) | IL265694A (enExample) |
| MX (1) | MX2019003895A (enExample) |
| SG (1) | SG10202103032QA (enExample) |
| WO (1) | WO2018067646A1 (enExample) |
| ZA (1) | ZA201902344B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2473565C2 (ru) | 2006-04-07 | 2013-01-27 | Аерпио Терапетикс, Инк. | АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ТИРОЗИН ФОСФАТАЗУ БЕТА ЧЕЛОВЕКА (HPTPβ), И ИХ ИСПОЛЬЗОВАНИЕ |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| JP2020518651A (ja) * | 2017-05-08 | 2020-06-25 | アスクレピクス セラピューティクス インコーポレイテッド | 抗血管新生ペプチドの持続送達のための生分解性微粒子 |
| US11674959B2 (en) | 2017-08-03 | 2023-06-13 | The Johns Hopkins University | Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors |
| CN113164597B (zh) | 2018-09-24 | 2025-02-28 | 视点制药公司 | 靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体 |
| CA3134816A1 (en) * | 2019-03-26 | 2020-10-01 | Asclepix Therapeutics, Inc. | Compositions and methods for treating ocular disease |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
| KR20240133892A (ko) * | 2023-02-28 | 2024-09-05 | 주식회사 파멥신 | 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE160821T1 (de) | 1990-06-11 | 1997-12-15 | Nexstar Pharmaceuticals Inc | Nukleinsäureliganden |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DK0773952T3 (da) | 1994-07-20 | 2004-03-22 | Inst Genetics Llc | Interaktionsfældesystemer til påvisning af proteininteraktioner |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| EP1696038B1 (en) | 1999-05-05 | 2010-06-02 | Phylogica Limited | Isolating biological modulators from biodiverse gene fragment libraries |
| US6794144B1 (en) | 1999-05-26 | 2004-09-21 | Licentia Ltd. | Methods and materials for generating SH3 domains with tailored binding properties |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132094A1 (en) | 2000-12-13 | 2004-07-08 | Michael Etzerodt | Combinatorial libraries of proteins having the scaffold structure of c-type lectinlike domains |
| AU2002323501C1 (en) | 2001-08-30 | 2010-04-29 | Biorexis Technology, Inc | Modified transferrin fusion proteins |
| JP5376747B2 (ja) | 2002-10-02 | 2013-12-25 | カタリスト バイオサイエンシーズ， インコーポレイテッド | 改変された特異性を有するプロテアーゼを作製する方法およびスクリーニングする方法 |
| WO2004063337A2 (en) | 2003-01-07 | 2004-07-29 | Dyax Corporation | Kunitz domain library |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| WO2007033215A2 (en) * | 2005-09-12 | 2007-03-22 | The Johns Hopkins University | Compositions having antiangiogenic activity and uses thereof |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| JP5600588B2 (ja) | 2007-06-01 | 2014-10-01 | ユニバーシティー オブ メリーランド，ボルティモア | 免疫グロブリン定常領域Ｆｃ受容体結合因子 |
| PE20090983A1 (es) * | 2007-11-09 | 2009-08-13 | Genentech Inc | Composiciones y metodos de uso de la quinasa-1 similar al receptor de la activina |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| MX2012000383A (es) * | 2009-07-07 | 2012-06-01 | Normoxys Inc | Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol. |
| EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| CA2858115A1 (en) | 2011-12-09 | 2013-06-13 | The Johns Hopkins University | Artificial antigen presenting cells having a defined and dynamic shape |
| ES2774217T3 (es) | 2013-06-07 | 2020-07-17 | Univ Johns Hopkins | Un péptido biomimético y una plataforma de administración biodegradable para el tratamiento de enfermedades dependientes de angiogénesis y linfangiogénesis |
-
2017
- 2017-10-04 EP EP17859077.4A patent/EP3522906B1/en active Active
- 2017-10-04 AU AU2017339970A patent/AU2017339970A1/en not_active Abandoned
- 2017-10-04 CN CN201780074408.5A patent/CN110177563A/zh active Pending
- 2017-10-04 KR KR1020197012909A patent/KR20190066040A/ko not_active Ceased
- 2017-10-04 SG SG10202103032QA patent/SG10202103032QA/en unknown
- 2017-10-04 EA EA201990868A patent/EA201990868A1/ru unknown
- 2017-10-04 BR BR112019006735A patent/BR112019006735A2/pt not_active Application Discontinuation
- 2017-10-04 WO PCT/US2017/055055 patent/WO2018067646A1/en not_active Ceased
- 2017-10-04 US US16/336,777 patent/US20190225670A1/en not_active Abandoned
- 2017-10-04 JP JP2019517873A patent/JP2019535651A/ja active Pending
- 2017-10-04 MX MX2019003895A patent/MX2019003895A/es unknown
- 2017-10-04 CA CA3038809A patent/CA3038809A1/en not_active Abandoned
-
2019
- 2019-03-28 IL IL265694A patent/IL265694A/en unknown
- 2019-04-12 ZA ZA2019/02344A patent/ZA201902344B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535651A5 (enExample) | ||
| HRP20201842T1 (hr) | Liječenje amd korištenjem aav2 varijante s afliberceptom | |
| JP2016539946A5 (enExample) | ||
| JP2017533201A5 (enExample) | ||
| JP2016065094A5 (enExample) | ||
| JP2019194251A5 (enExample) | ||
| JP2016516073A5 (enExample) | ||
| JP2016528202A5 (enExample) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| Hennig et al. | Nanoparticles for the treatment of ocular neovascularizations | |
| MX383971B (es) | Composición farmacéutica para la prevención y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteína de fusión en la cual el péptido que penetra el tejido y la preparación del factor de crecimiento endotelial antivascular se fusionan. | |
| NZ595063A (en) | Polypeptides from neisseria meningitidis | |
| JP2016509011A5 (enExample) | ||
| JP2016521712A5 (enExample) | ||
| JP2019203035A5 (enExample) | ||
| JP2018509388A5 (enExample) | ||
| JP2018505882A5 (enExample) | ||
| JP2017503014A5 (enExample) | ||
| JP2020518651A5 (enExample) | ||
| JP2016536369A5 (enExample) | ||
| JP2016517421A5 (enExample) | ||
| MX2019005466A (es) | Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. | |
| JP2018508528A5 (enExample) | ||
| JP2014518211A5 (enExample) | ||
| JP2009538916A5 (enExample) |